Advertisement
IMDX vs VNRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMDX is a StrongBuy and VNRX is a StrongBuy.
IMDX's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for IMDX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 28 of the 31 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMDX advanced for three days, in 165 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
IMDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMDX as a result. In 83 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for IMDX turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMDX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.348) is normal, around the industry mean (65.617). P/E Ratio (-1.862) is within average values for comparable stocks, (2.429). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. IMDX's P/S Ratio (71.942) is very high in comparison to the industry average of (9.775).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. IMDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
VNRX in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 12, 2026
VNRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 42 of 46 cases where VNRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where VNRX advanced for three days, in 147 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VNRX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.163) is normal, around the industry mean (2.906). P/E Ratio (-0.045) is within average values for comparable stocks, (2.003). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.767) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. VNRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
IMDX | VNRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 47 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 86 | 96 | |
P/E GROWTH RATING 1..100 | 12 | 6 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VNRX's Valuation (47) in the Medical Or Nursing Services industry is in the same range as IMDX (65) in the Medical Specialties industry. This means that VNRX’s stock grew similarly to IMDX’s over the last 12 months.
VNRX's Profit vs Risk Rating (100) in the Medical Or Nursing Services industry is in the same range as IMDX (100) in the Medical Specialties industry. This means that VNRX’s stock grew similarly to IMDX’s over the last 12 months.
VNRX's SMR Rating (100) in the Medical Or Nursing Services industry is in the same range as IMDX (100) in the Medical Specialties industry. This means that VNRX’s stock grew similarly to IMDX’s over the last 12 months.
IMDX's Price Growth Rating (86) in the Medical Specialties industry is in the same range as VNRX (96) in the Medical Or Nursing Services industry. This means that IMDX’s stock grew similarly to VNRX’s over the last 12 months.
VNRX's P/E Growth Rating (6) in the Medical Or Nursing Services industry is in the same range as IMDX (12) in the Medical Specialties industry. This means that VNRX’s stock grew similarly to IMDX’s over the last 12 months.
| IMDX | VNRX | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 90% | 3 days ago 86% |
| Stochastic ODDS (%) | 3 days ago 80% | 3 days ago 81% |
| Momentum ODDS (%) | 3 days ago 90% | N/A |
| MACD ODDS (%) | 3 days ago 90% | N/A |
| TrendWeek ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| TrendMonth ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| Advances ODDS (%) | 26 days ago 79% | 3 days ago 74% |
| Declines ODDS (%) | 3 days ago 90% | 5 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 90% | 3 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMDX’s FA Score shows that 1 FA rating(s) are green while VNRX’s FA Score has 1 green FA rating(s).
- IMDX’s FA Score: 1 green, 4 red.
- VNRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMDX’s TA Score shows that 4 TA indicator(s) are bullish while VNRX’s TA Score has 4 bullish TA indicator(s).
- IMDX’s TA Score: 4 bullish, 4 bearish.
- VNRX’s TA Score: 4 bullish, 2 bearish.
Price Growth
IMDX (@Medical Specialties) experienced а -5.98% price change this week, while VNRX (@Medical/Nursing Services) price change was -3.33% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.55%. For the same industry, the average monthly price growth was -5.91%, and the average quarterly price growth was +42.02%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.51%. For the same industry, the average monthly price growth was -9.72%, and the average quarterly price growth was -10.64%.
Reported Earning Dates
IMDX is expected to report earnings on Nov 09, 2026.
VNRX is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Medical Specialties (+1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-0.51% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| KURE | 17.85 | 0.35 | +2.00% |
| KraneShares MSCI All China Health Care Index ETF (KURE) | |||
| QBTX | 10.65 | 0.02 | +0.19% |
| Tradr 2X Long QBTS Daily ETF (QBTX) | |||
| LIAE | 192.27 | N/A | N/A |
| LifeX 2050 Inflation-Protected Longevity Income ETF (LIAE) | |||
| CGUI | 25.29 | -0.01 | -0.04% |
| Capital Group Ultra Short Income ETF (CGUI) | |||
| SCCR | 24.64 | -0.04 | -0.16% |
| Schwab Core Bond ETF (SCCR) | |||
IMDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMDX has been loosely correlated with STRRP. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if IMDX jumps, then STRRP could also see price increases.
| Ticker / NAME | Correlation To IMDX | 1D Price Change % | ||
|---|---|---|---|---|
| IMDX | 100% | -0.35% | ||
| STRRP - IMDX | 37% Loosely correlated | -1.64% | ||
| FATE - IMDX | 31% Poorly correlated | +0.96% | ||
| NEPH - IMDX | 30% Poorly correlated | +0.28% | ||
| GOSS - IMDX | 29% Poorly correlated | +1.53% | ||
| BMRN - IMDX | 29% Poorly correlated | -1.20% | ||
More | ||||
VNRX and
Correlation & Price change
A.I.dvisor tells us that VNRX and LAB have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VNRX and LAB's prices will move in lockstep.
| Ticker / NAME | Correlation To VNRX | 1D Price Change % | ||
|---|---|---|---|---|
| VNRX | 100% | +2.96% | ||
| LAB - VNRX | 28% Poorly correlated | -4.72% | ||
| STRRP - VNRX | 27% Poorly correlated | -1.64% | ||
| SSII - VNRX | 26% Poorly correlated | -5.06% | ||
| BMRA - VNRX | 26% Poorly correlated | +2.34% | ||
| IMDX - VNRX | 24% Poorly correlated | -0.35% | ||
More | ||||